Vitamin D effect on growth and vitamin D metabolizing enzymes in triple-negative breast cancer

Anticancer Research

Volumn 35, Issue 2, 2015, Pages 805-810

  Richards, Sarah E ^a   Weierstahl, Kaytie A ^a   Kelts, Jessica L ^a  

^a UNIVERSITY OF MICHIGAN FLINT   (United States)

Author keywords

25 hydroxyvitamin D; Breast cancer; CYP24A1; CYP27B1; Triple negative breast cancer; Vitamin D; Vitamin D receptor

Indexed keywords

CALCIFEDIOL; CALCITRIOL; COLECALCIFEROL 24 HYDROXYLASE; CYTOCHROME; CYTOCHROME P450 27B1; UNCLASSIFIED DRUG; VITAMIN D RECEPTOR; CALCITRIOL RECEPTOR; CYP24A1 PROTEIN, HUMAN; MESSENGER RNA; VITAMIN D;

ARTICLE; BREAST CANCER CELL LINE; CANCER INHIBITION; CELL VIABILITY; CONTROLLED STUDY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRIPLE NEGATIVE BREAST CANCER; VITAMIN METABOLISM; CELL DIVISION; DRUG EFFECTS; ENZYMOLOGY; FEMALE; GENETICS; HUMAN; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

CELL DIVISION; CELL LINE, TUMOR; FEMALE; HUMANS; RECEPTORS, CALCITRIOL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRIPLE NEGATIVE BREAST NEOPLASMS; VITAMIN D; VITAMIN D3 24-HYDROXYLASE;

EID: 84923645952     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Brenton JD, Carey LA, Ahmed AA and Caldas C: Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol 23(29): 7350-7360, 2005.
2. Harris LN, Broadwater G, Lin NU, Miron A, Schnitt SJ, Cowan D, Lara J, Bleiweiss I, Berry D, Ellis M, Hayes DF, Winer EP and Dressler L: Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342. Breast Cancer Res 8(6): R66, 2006.
3. Yao S and Ambrosone CB: Associations between vitamin D deficiency and risk of aggressive breast cancer in African-American women. J Steroid Biochem Mol Biol 136: 337-341, 2013.
4. Tangpricha V, Pearce EN, Chen TC and Holick MF: Vitamin D insufficiency among free-living healthy young adults. Am J Med 112(8): 659-662, 2002.
5. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad MH and Weaver CM: Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96(7): 1911-1930, 2011.
6. Berger U, McClelland RA, Wilson P, Greene GL, Haussler MR, Pike JW, Colston K, Easton D and Coombes RC: Immunocytochemical determination of estrogen receptor, progesterone receptor, and 1,25-dihydroxyvitamin D3 receptor in breast cancer and relationship to prognosis. Cancer Res 51(1): 239-244, 1991.
7. Yao S, Sucheston LE, Millen AE, Johnson CS, Trump DL, Nesline MK, Davis W, Hong CC, McCann SE, Hwang H, Kulkarni S, Edge SB, O'Connor TL and Ambrosone CB: Pretreatment serum concentrations of 25-hydroxyvitamin D and breast cancer prognostic characteristics: a case-control and a case-series study. PLoS One 6(2): e17251, 2011.
8. Goodwin PJ, Ennis M, Pritchard KI, Koo J and Hood N: Prognostic effects of 25-hydroxyvitamin D levels in early breast cancer. J Clin Oncol 27(23): 3757-3763, 2009.
9. Hoadley KA, Weigman VJ, Fan C, Sawyer LR, He X, Troester MA, Sartor CI, Rieger-House T, Bernard PS, Carey LA and Perou CM: EGFR associated expression profiles vary with breast tumor subtype. BMC Genomics 8: 258, 2007.
10. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, Akslen LA, Ragaz J, Gown AM, Gilks CB, van de Rijn M and Perou CM: Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10(16): 5367-5374, 2004.
11. Kennedy RD, Quinn JE, Mullan PB, Johnston PG and Harkin DP: The role of BRCA1 in the cellular response to chemotherapy. J Natl Cancer Inst 96(22): 1659-1668, 2004.
12. Litzenburger BC, Creighton CJ, Tsimelzon A, Chan BT, Hilsenbeck SG, Wang T, Carboni JM, Gottardis MM, Huang F, Chang JC, Lewis MT, Rimawi MF and Lee AV: High IGF-IR Activity in Triple-Negative Breast Cancer Cell Lines and Tumorgrafts Correlates with Sensitivity to Anti-IGF-IR Therapy. Clin Cancer Res 17(8): 2314-2327, 2011.
13. Malinen M, Ryynanen J, Heinaniemi M, Vaisanen S and Carlberg C: Cyclical regulation of the insulin-like growth factor binding protein 3 gene in response to 1alpha,25-dihydroxyvitamin D3. Nucleic Acids Res 39(2): 502-512, 2011.
14. Malinen M, Huttunen T and Kaipio JP: Thermal dose optimization method for ultrasound surgery. Phys Med Biol 48(6): 745-762, 2003.
15. Shen Z, Zhang X, Tang J, Kasiappan R, Jinwal U, Li P, Hann S, Nicosia SV, Wu J and Bai W: The coupling of epidermal growth factor receptor down regulation by 1alpha,25-dihydroxyvitamin D3 to the hormone-induced cell cycle arrest at the G1-S checkpoint in ovarian cancer cells. Mol Cell Endocrinol 338(1-2): 58-67, 2011.
16. Holick MF: Vitamin D and sunlight: strategies for cancer prevention and other health benefits. Clin J Am Soc Nephrol 3(5): 1548-1554, 2008.
17. Masuda S and Jones G: Promise of vitamin D analogues in the treatment of hyperproliferative conditions. Mol Cancer Ther 5(4): 797-808, 2006.
18. Peehl DM, Skowronski RJ, Leung GK, Wong ST, Stamey TA and Feldman D: Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells. Cancer Res 54(3): 805-810, 1994.
19. Cantor I: Shedding light on vitamin D and integrative oncology. Integr Cancer Ther 7(2): 81-89, 2008.
20. Fleet JC: Molecular actions of vitamin D contributing to cancer prevention. Mol Aspects Med 29(6): 388-396, 2008.
21. Krishnan AV and Feldman D: Mechanisms of the anti-cancer and anti-inflammatory actions of vitamin D. Annu Rev Pharmacol Toxicol 51: 311-336, 2011.
22. Simboli-Campbell M, Narvaez CJ, Tenniswood M and Welsh J: 1,25-Dihydroxyvitamin D3 induces morphological and biochemical markers of apoptosis in MCF-7 breast cancer cells. J Steroid Biochem Mol Biol 58(4): 367-376, 1996.
23. Welsh J: Induction of apoptosis in breast cancer cells in response to vitamin D and antiestrogens. Biochem Cell Biol 72(11-12): 537-545, 1994.
24. Buras RR, Schumaker LM, Davoodi F, Brenner RV, Shabahang M, Nauta RJ and Evans SR: Vitamin D receptors in breast cancer cells. Breast Cancer Res Treat 31(2-3): 191-202, 1994.
25. Lou YR, Molnar F, Perakyla M, Qiao S, Kalueff AV, St-Arnaud R, Carlberg C and Tuohimaa P: 25-Hydroxyvitamin D(3) is an agonistic vitamin D receptor ligand. J Steroid Biochem Mol Biol 118(3): 162-170, 2010.
26. Flanagan L, Packman K, Juba B, O'Neill S, Tenniswood M and Welsh J: Efficacy of Vitamin D compounds to modulate estrogen receptor negative breast cancer growth and invasion. J Steroid Biochem Mol Biol 84(2-3): 181-192, 2003.
27. LaPorta E and Welsh J: Modeling vitamin D actions in triple negative/basal-like breast cancer. J Steroid Biochem Mol Biol 144 Pt A: 65-73, 2014.
28. Stambolsky P, Tabach Y, Fontemaggi G, Weisz L, Maor-Aloni R, Siegfried Z, Shiff I, Kogan I, Shay M, Kalo E, Blandino G, Simon I, Oren M and Rotter V: Modulation of the vitamin D3 response by cancer-associated mutant p53. Cancer Cell 17(3): 273-285, 2010.
29. Punj V, Bhattacharyya S, Saint-Dic D, Vasu C, Cunningham EA, Graves J, Yamada T, Constantinou AI, Christov K, White B, Li G, Majumdar D, Chakrabarty AM and Das Gupta TK: Bacterial cupredoxin azurin as an inducer of apoptosis and regression in human breast cancer. Oncogene 23(13): 2367-2378, 2004.
30. Takeyama K, Kitanaka S, Sato T, Kobori M, Yanagisawa J and Kato S: 25-Hydroxyvitamin D3 1alpha-hydroxylase and vitamin D synthesis. Science 277(5333): 1827-1830, 1997.
31. Lopes N, Sousa B, Martins D, Gomes M, Vieira D, Veronese LA, Milanezi F, Paredes J, Costa JL and Schmitt F: Alterations in Vitamin D signalling and metabolic pathways in breast cancer progression: a study of VDR, CYP27B1 and CYP24A1 expression in benign and malignant breast lesions. BMC Cancer 10: 483, 2010.
32. Diesing D, Cordes T, Fischer D, Diedrich K and Friedrich M: Vitamin D - metabolism in the human breast cancer cell line MCF-7. Anticancer Res 26(4A): 2755-2759, 2006.
33. Horvath E, Lakatos P, Balla B, Kosa JP, Tobias B, Jozilan H, Borka K, Horvath HC, Kovalszky I and Szalay F: Marked increase of CYP24A1 mRNA level in hepatocellular carcinoma cell lines following vitamin D administration. Anticancer Res 32(11): 4791-1496, 2012.
34. Swami S, Raghavachari N, Muller UR, Bao YP and Feldman D: Vitamin D growth inhibition of breast cancer cells: gene expression patterns assessed by cDNA microarray. Breast Cancer Res Treat 80(1): 49-62, 2003.
35. Kosa JP, Horvath P, Wolfling J, Kovacs D, Balla B, Matyus P, Horvath E, Speer G, Takacs I, Nagy Z, Horvath H and Lakatos P: CYP24A1 inhibition facilitates the anti-tumor effect of vitamin D3 on colorectal cancer cells. World J Gastroenterol 19(17): 2621-2628, 2013.
36. Garcia-Quiroz J, Garcia-Becerra R, Barrera D, Santos N, Avila E, Ordaz-Rosado D, Rivas-Suarez M, Halhali A, Rodriguez P, Gamboa-Dominguez A, Medina-Franco H, Camacho J, Larrea F and Diaz L: Astemizole synergizes calcitriol antiproliferative activity by inhibiting CYP24A1 and upregulating VDR: a novel approach for breast cancer therapy. PLoS One 7(9): e45063, 2012.